ReNeuron Group plc

("ReNeuron" or the "Company")

Director/PDMR Interest in Share Options

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that the following share option grants have been awarded today under the Company's Long Term Incentive Plan (the "Plan") and Non-Executive Share Option Scheme (the "NED Plan") to certain directors listed below.

An award of 200,000 share options has been granted to Iain Ross under the NED Plan in accordance with his letter of appointment; 100,000 of the options have been granted with a nominal exercise price of one (1) pence each and 100,000 of the options have an exercise price of 107.0 pence each (being the closing mid-market price of the Company's shares on the last business day before Iain's date of appointment). The options vest on a straight line basis over three years and are exercisable if the share price of the Company's shares exceeds 200 pence for a period of 30 consecutive days subsequent to the award.

An award of 464,136 share options has been granted to Catherine Isted under the Plan in accordance with her letter of appointment with all options vesting from the third anniversary of the award; 232,068 of the options have been granted with a nominal exercise price of one (1) pence each and are exercisable if the Company's shareholder return meets or exceeds that of the FTSE AIM Healthcare Index in any three-year period from date of grant; 232,068 of the options have an exercise price of 94.8 pence each (being the closing mid-market price of the Company's shares on the last business day before Catherine's date of appointment) and are not subject to any performance conditions. 

An award of 83,578 share options has been granted to Olav Hellebø under the Plan in connection with the Company's remuneration policy whereby executive Directors are eligible to earn a non-cash bonus payable in the form of share options based on the achievement of certain objectives in the year to 31 March 2021. In line with the terms of the Plan and the Company's remuneration policy, these share options are exercisable from the second anniversary of the award and are not subject to performance conditions. The number of options granted is determined by the equivalent cash value of the bonus earned divided by the market value of shares, in this case market value being the closing mid-market price of the Company's shares the day before the grant was approved.

Share option grants are deemed accepted by the option holder unless expressly rejected within a period of 30 days from the date of grant.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

                                                                                                                ENDS

Contacts:

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 (Disclosure in relation to share options granted to Directors and PDMRs)